CRISPR Therapeutics AGCRSPEarnings & Financial Report
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. I...
CRSP Q4 FY2024 Key Financial Metrics
Revenue
$35.7M
Gross Profit
N/A
Operating Profit
$-64.6M
Net Profit
$-37.3M
Gross Margin
N/A
Operating Margin
-181.0%
Net Margin
-104.5%
YoY Growth
-82.3%
EPS
$-0.41
CRISPR Therapeutics AG Q4 FY2024 Financial Summary
CRISPR Therapeutics AG reported revenue of $35.7M (down 82.3% YoY) for Q4 FY2024, with a net profit of $-37.3M (down 141.8% YoY) (-104.5% margin).
Key Financial Metrics
| Total Revenue | $35.7M |
|---|---|
| Net Profit | $-37.3M |
| Gross Margin | N/A |
| Operating Margin | -181.0% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
CRISPR Therapeutics AG Q4 FY2024 revenue of $35.7M breaks down across 2 segments, led by Collaboration Revenue at $35.0M (98.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Collaboration Revenue | $35.0M | 98.1% |
| Grant | $2.3M | 6.5% |
CRISPR Therapeutics AG Annual Revenue by Year
CRISPR Therapeutics AG annual revenue history includes year-by-year totals (for example, 2023 revenue was $371.2M).
CRISPR Therapeutics AG Quarterly Revenue & Net Profit History
CRISPR Therapeutics AG results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $35.7M | -82.3% | $-37.3M | -104.5% |
| Q4 FY2023 | $201.2M | +3353333.3% | $89.3M | 44.4% |
| Q3 FY2023 | $0 | — | $-112.2M | N/A |
| Q2 FY2023 | $70.0M | +44203.8% | $-77.7M | -111.1% |
| Q1 FY2023 | $100.0M | +10538.3% | $-53.1M | -53.1% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q4 2024 | |
|---|---|---|---|---|---|
| Revenue | $100.0M | $70.0M | $0 | $201.2M | $35.7M |
| YoY Growth | 10538.3% | 44203.8% | N/A | 3353333.3% | -82.3% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q4 2024 | |
|---|---|---|---|---|---|
| Assets | $2.24B | $2.20B | $2.09B | $2.23B | $2.24B |
| Liabilities | $389.5M | $381.0M | $359.0M | $346.8M | $310.0M |
| Equity | $1.85B | $1.82B | $1.73B | $1.88B | $1.93B |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q4 2024 | |
|---|---|---|---|---|---|
| Operating CF | $8.8M | $-133.2M | $-39.9M | $-96.1M | $-50.0M |